HomeEducationTherapy AreasResourcesMedicinesStarter PacksEvents
Log inRegister

Breakthrough cancer pain: Rapid-onset opioids or short-acting opioids?

Published 28th April 2023
Article
10 mins read

When selecting an appropriate opioid treatment for BTcP, it is important to consider the pharmacokinetic properties of the treatment.

Long acting or short acting opioids

Sign up to MediScene

To access this content, please register or log in.

Log inSign up

Experience the full suite of Mediscene features such as:

Personalised content
Valuable resources, education and information within a variety of therapeutic areas
Patient Support
Access information about the therapeutic options available for patients
Education Modules
Access to educational modules and self-paced online learning
Product Information
Easy access to the Menarini portfolio
Events
Explore upcoming events related to your areas of interest
Clinical Resources
Access to comprehensive tools designed to support you and your patients
References
  1. Davies AN et al. Eur J Pain 2009;13(4):331–8.
  2. Davies A et al. J Pain Symptom Manag 2013;46(5):619–28.
  3. Vellucci R et al. Drugs 2016;76:315–30.
  4. Simon SM et al. J Opioid Manag 2014;10:207–15.
  5. World Health Organization. Cancer Pain Relief. World Health Organization, 1986.
    Available from: https://apps.who.int/iris/bitstream/handle/10665/43944/9241561009_eng.pdf
  6. Smith HS. Ann Palliat Med 2012;1(1):45–52.